Editorial comment from Dr Olbert to Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.
Olbert
Peter J
PJ
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000634:Aminoquinolines / Q000494:pharmacology*; D000818:Animals; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D004195:Disease Models, Animal; D000077271:Imiquimod; D008562:Membrane Glycoproteins / Q000819:agonists*; D051379:Mice; D051199:Toll-Like Receptor 7 / Q000819:agonists*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D008562:Membrane Glycoproteins; C477038:Tlr7 protein, mouse; D051199:Toll-Like Receptor 7; D000077271:Imiquimod